India’s ability to produce affordable generic drugs has led to the country’s reputation of being the “pharmacy of the world,” according to Dr. Reddy’s Vice President Radha Iyer.
The U.S. FDA issued a new draft guidance for drugmakers aiming their resources at Fabry disease, a rare genetic disease.
German drugmaker Bayer signed an alliance with Arvinas Inc. to gain access to the U.S. biotech firm’s experimental protein drugs and crop protection technology in a deal worth up to $750 million.
The pharmaceutical industry’s greatest value lies in the quality of life that its drugs provide – plus the innovative programs that help support adherence and education.
Bayer is looking into future options for the established drugs business, partly because of price pressure in China, the German company’s head of pharmaceuticals said.
The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
Merck & Co. announced that the U.S. Food and Drug Administration accepted for review supplemental New Drug Applications (sNDAs) for Pifeltro and Delstrigo.
Dr. Robert Redfield, the new head of the U.S. Centers for Disease Control and Prevention, boldly predicted in April 2018 that the AIDS epidemic can be defeated by 2025. Merck, Janssen and Gilead Sciences all released clinical data for HIV treatments that could make Redfield’s prediction a reality.
An experimental HIV immunotherapy treatment is showing significant promise in clinical testing. A study shows the two-drug combination is capable of suppressing HIV for months at a time.
With smart cancer diagnostics, one-stop-shop diabetes kits and AI systems to improve ambulance pick-ups for patients with chest pain, AstraZeneca aims to move from simply supplying drugs to become a broad healthcare provider in China.